Market Scenario  

Stem cell therapy market was valued at US$ 394.50 million in 2024 and is projected to hit the market valuation of US$ 2,612.92 million by 2033 at a CAGR of 23.97% during the forecast period 2025–2033.

Stem cell therapy is the future of regenerative medicine, which could potentially treat numerous chronic or degenerative diseases. As per latest data published in 2023, it was reported that there was a total of 4,749 registered clinical trials worldwide looking into stem cell therapy market out of which the United States alone had more than 1,200 active trials, while China and Europe had the rest. Looking into mesenchymal stem cells, which are the most studied as of October 2023, there have been more than 1,300 trials for various diseases associated with these stem cells including Crohn’s disease, stroke, and osteoarthritis. On the other hand, pluripotent stem cells which included recently induced pluripotent stem cells (iPS), were slowly beginning to enter the clinical realm, confirming the use of induced form for more than over 250 registers clinical trials for treating spine and Parkinson’s diseases along with diabetes. Out of these particular studies, 204 active registries were accessible to patients in 2023, giving hope for the realization in application of experiments.

The ability to develop stem cell therapy is still very much affected by the regulatory framework. By the year 2023, the FDA had approved 23 stem cell therapy products, most of which are for hematopoietic stem cell transplantation (HSCT), which are mainly to treat blood cancers like leukemia and lymphoma. The most recent approval in the stem cell therapy market was of Ryoncil (remestemcel-L), a product of Mesoblast that is targeted at treating steroid-refractory acute graft-versus-prevacid in children. In Japan, there have been 8 regenerative stem cell products which have been approved under its accelerated framework that include heart failure treatment and cartilage regeneration as well. Conversely, Europe has had six advanced therapy medicinal products (ATMP) approved which contain stem cells, Holoclar included which is used for corneal injury. However, even with these advances the regulatory environment is still quite rigid and only a small percentage of the stem cell therapies being tested make it to the market.

Today, companies in the stem cell therapy market such as Mesoblast, Athersys and BlueRock Therapeutics are furthering pipelines aimed at heart failure, stroke and neurodegenerative diseases. For example, Athersys’ MultiStem therapy has demonstrated potential in the late stages of development for the treatment of Ischemic stroke. Meanwhile, California has spent US$ 3 billion in stem cell research and generated 56,000 jobs and an extra US$ 10 billion to its economy, these statistics alone showcase the wider social impact of the stem cell therapy in North America alone. With the help of progress in manufacturing, gene editing and scalable therapies, the stem cell therapy is likely to be the major medicine in the years to come.  

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Increasing Prevalence of Chronic Diseases Driving Demand for Regenerative and Cell-Based Therapeutic Solutions

There has been a global increase in the prevalence of chronic illnesses over the years which has, in turn, led to a heightened interest in stem cell therapy market. As per the World Health Organization, there are approximately 41 million deaths that can be attributed to chronic illnesses every year which represents approximately 71% of all deaths globally. The International Diabetes Federation states that there are at least 463 million people who are confirmed as adults suffering from diabetes all across the globe. In the United States of America, the American Cancer Society claimed that there would be 19.3 million new cases of cancer in the year 2023. On top of that, cardiovascular diseases reportedly affect around 523 million individuals which indicates the rate at which chronic disease conditions are spreading. The above statistics clearly show that there is a dire need for advanced and more efficient treatment measures to be made available.

Similarly, the increase in cases related to Alzheimer and Parkinson also add to the need for stem cell therapy market. According to the Alzheimer’s Disease International, there are over 55 million people who have dementia which is a number that is expected to double in every two decades which requires an ample amount of attention. Effects of Parkinson’s disease are faced by more than 10 million people around the globe according to the Parkinson’s foundation. To add on, the Global Burden of Disease Study is reported to have stated that musculoskeletal problems alone are faced by 1.71 billion people on this planet. The higher the number of diseases develops the more apparent it shows the need for stem cell therapies in this sector.

As the scope of regenerative medicine expands in the stem cell therapy market, investment in stem cell research increases in tandem. From the standpoint of the global investment panorama in transplant medicine, 2023 marks a significant increase with the ‘regenerative medicine’ category. In comparison, there are more than 1,200 ongoing clinical trials related to cell therapy situated in the US and Canada, according to clinicaltrials.gov. 

Trend : Emergence of Induced Pluripotent Stem Cells (iPSCs) Revolutionizing Personalized Medicine and Therapeutic Applications Globally

Induced pluripotent stem cells (iPSCs) marks a shift from traditional medicine practice into personalized medicine where patients derived products are generated. As of 2023, PubMed shows more than 7,000 research articles which depict a great scientific interest in the stem cell therapy market. CiRA Foundation at the Kyoto University has established a stock of 30 iPSC lines to be used clinically. A major milestone was made in 2023 when the FDA approved clinical trial ind iPSC derived retinal cells for age related macular- degeneration. Similarly, Fate Therapeutics launched several clinical trials targeting cancer with iPSC-derived natural killer cells. 

In 2023, the global market of iPSC technology is expected to reach over $3 billion. Due to an anticipated sharp increase in demand, Fujifilm Cellular Dynamics intended to create more than $10 billion of producing plant derived cells annually. BlueRock Therapeutics with the backing of Bayer AG has poured $1billion into the iPSC-therapy business and investment integration has become rapid. Between 2013 and 2023, the Japanese government funded iPSC research around $ 1 billion showing the commitment of the state. In the US the California Institute for Regenerative Medicine funded $2.5 billion in grants for stem cell research including iPSC.

Today, more than 50 iPSC-derived clinical trials are in progress throughout the global stem cell therapy market, as posted on ClinicalTrials.gov in 2023. Cynata Therapeutics completed a Phase II trial using osteoarthritis treating iPSC-derived mesenchymal stem cells. Cardiovascular research, using iPSC-derived cardiomyocytes modeling of heart diseases and drug discovery are gradually on. The Stem Cell & Regenerative Medicine International started a trial involving the use of iPSC derived neural cells for spinal cord injury. These developments illustrate the efficacy that iPSCs can bring about in a number of areas to deliver medicine in a more personalized and effective manner.

Challenge: High Therapy Costs and Manufacturing Complexities Limiting Accessibility and Widespread Adoption of Treatments

As per recently published reports from the Mayo Clinic, the average cost of stem cell therapy to vary between $5000 and $50,000, depending on the type of condition and the treating clinic. Furthermore, the National Cancer Institute cites statistics indicating that some forms of advanced therapy, such as CAR-T cell treatment, may cost more than $200,000 per patient in the stem cell therapy market. The process of creating autologous stem cells therapy is expensive, with costs of greater than $100,000 for each patient because of process that is unique to that patient, from Alliance for Regenerative Medicine. In most cases, such costs are a hindrance for organizations and even people without good financial means or health insurance.

Increased manufacturing complexities add significantly onto these costs.  In 2023, the global numbers of Good Manufacturing Practice (GMP)- qualified cell therapy’s production centers were approximately 500. The construction of a GMP facility is very expensive, at least $20 million needed to be invested in specialized equipment and clean spaces in the beginning. Also, stem cell therapy production is rather complicated, for example, the process of cell expansion and differentiating can last for weeks therefore raising labor and running costs. There are further expenses in regards to logistics, as the temperature of live cells needs to be controlled and according to BioPharma Logistics shipping costs can go from $2000 – $10000 per batch.

Lack of reimbursement further worsens the issue of accessibility in the stem cell therapy market. A survey done by the American Society of Hematology in 2023 showed that approximately 60% of providers of hematology faced rejection by the insurance company to carry out stem cells transplant procedures. Stem cell therapy coverage under Medicare and Medicaid is very poor and can only cover some approved indications. The insurance companies are reluctant to offer coverage due to the lack of set pricing models and different outcomes of clinical trials. 

Segmental Analysis 

By Cell Source 

Adipose tissue-derived mesenchymal stem cells (AD-MSCs) have gained prominence over other cell sources by controlling more than 40.41% of the stem cell therapy market due to their abundance and ease of access. On average, the human body carries about 14 kilograms of adipose tissue which, in comparison with other sources, is the source of stem cells that makes the most sense. Adipose tissue has relatively a high concentration of MSCS, hence allowing easy extraction. Wherein, it is reported that only about 1,000 to 10,000 MSCs can be obtained from every gram of bone marrow aspirates, adipose tissue comes in handy by containing about 500,000 MSCs per gram of tissue. Such high yields can help in eliminating prolonged cell expansions in vitro, facilitating the cells in second ways of therapeutic production. Adipose tissue in contrary is less complicated as most of these procedures require liposuction, which takes less than an hour. Adipose extraction processes comes off less complicated and uncomfortable than bone marrow extraction and a bone marrow extraction requires sedations that has further risks of the patient bleeding or getting infected. Recent published papers indicates that AD-MSC has a strong ability to proliferate, and can double in numbers in a span of 40 hours given the right temperature and settings. 

Other relevant issues for AD-MSC stem cell therapy market growth are new methods of separation and growing number of clinical trials. In 2023, there are more than 250 clinical trials underway examining AD-MSCs for a range of conditions, including osteoarthritis, over 30 of which are dedicated to knee osteoarthritis therapy.

Recent advancements in technology have made it possible to create automated sealed systems for stem cell harvesting, limiting the manual work needed to less than an hour and a half. Furthermore, interest in AD-MSCs markets is also reinforced with huge funding, as more than US$ 1.5 billion have been directed to stem cell companies concentrating on adipose-derived therapies over the last two years. Moreover, only since 2021, collaborations between biotechnology companies and research organizations have led to the development of more than 15 patented technologies related to AD-MSCs, indicating a very active and competitive market.

By Type 

Autologous stem cell therapy is the most popular in the stem cell therapy market with revenue share of over 76.56% because it is less likely to be rejected by the immune system. In these autologous therapies, stem cells are taken from the patient’s own body so the potential for developing the graft versus host disease which is a major risk for the allogeneic transplant is removed. According to reports, about 80% of stem cell transplants done for blood cancers across the globe are autologous transplants affirming to their strength in practice. Additionally, overall survival rate has been improved significantly in autologous stem cell therapy. For instance, patients with multiple myeloma who underwent an autologous hematopoietic stem cell transplant have resulted in median survival of more than 60 months.

Advancements in cell therapeutic and the supportive regulatory environment have been the catalyzing forces for autologous stem cell therapy market growth. The point-of-care technologies provide the potential to fast track the separation and reinfusion of stem cells, reducing processing time from days to mere hours. In relation, there are more than 10 autologous stem cell products that have been approved by the FDA, which were under accelerated review, in order to meet unfulfilled clinical needs in the market. In line with this, the global funding for companies engaged autologous stem cell therapy reached US$ 2.3 billion through venture capital since 2020. In addition, the surveys conducted in 2023. show even 65% of the patients prefer autologous treatments because of the safety perceptions. Another reason is reimbursement policies in a number of countries are more favorable for autologous therapies because there are already residents of over 20 national health care systems covered by such treatments. 

By Therapeutic Use

On the basis of the therapeutic application, oncology accounts for close to 26% of the stem cell therapy market. By the end of 2023, over 20 stem cell therapies had been approved by the FDA for treating cancer. The majority concentrate on HSCT for leukemias and lymphomas. This indicates the importance of HSCT in the treatment of oncology as it has been performed more than 50,000 times and each year it gets better and advances more. In 2023, WHO’s findings showed that there were 19.3 million global new cancer cases, which has further added fuel to need for novel therapies. In more definite terms, stem cell treatment has the potential to improve five-year survival rate of certain cancers up to a staggering 70%, and improves the life of patients tremendously. With over 300 ongoing clinical trials in 2023, oncology focused stem cells research have grown to more than US$ 5 billion in the last three years.

In addition, the scope of stem cell therapies has improved significantly, with the ability to tailor the therapies to specific cancer cells due to gene editing technologies such as CRISPR-Cas9. Indeed, some structural factors already contribute to this growth, such as the United States Government's Cancer Moonshot initiative that spent over $1.8 billion on cancer research over a span of seven years. Furthermore, synergies between pharmaceutical and biotechnology companies in the stem cell therapy market have resulted in the commercialization of new therapies, which is an outcome of more than 15 collaborative deals signed in two years. These initiatives focus on widening the potential applications of stem cell therapy on oncology and further reinforce the importance of this technology in the marketplace.

By Delivery Method

The in vivo delivery method is the most prominent segment in the stem cell therapy market commanding over 56.35 % share due to its target applications and improved outcomes. In-vivo delivery comprises stem cell injections directly into the recipient body which then migrate towards the corresponding tissues and exert therapeutic effects. As per latest data analysis,  the method is heavily preferred in more than 60 recent clinical trial engaged in stem cell therapies. Moreover, it is proving to be more efficient in the treatment of heart diseases. Wherein, intramyocardial injection of stem cells has been associated with the observed left ventricular ejection fraction increased by 15% in patients suffering from ischemic cardiomyopathy.

Major advancements in targeting and delivering mechanisms have made it easier for in-vivo methods to gain popularity. Technologies such as nanoparticle carriers and hydrogel scaffolds in some studies were able to boost the retention efficiency of stem cells in target locations to 80%, this is according to studies from the engineering side of medicine. In addition, non-invasive imaging methods such as MRI, PET etc., permit tracking of stem cells in vivo, therefore offering valuable information about the stem cells migration and engraftment. Additionally, the legal position in America has also support the in-vivo methods, as approximately over a dozen in vivo stem cell therapies have received a fast-track designation from the FDA from around the year 2021.

The invention of in-vivo delivery method is changing stem cell therapy market dynamics providing faster translation of stem cell research into clinical therapies. Moreover, the synergistic collaborations between organizations in the biotechnology industry and those in the medical device field saw the design and manufacture of targeted catheters and delivery systems, with about 25 new devices manufactured and sold to the market since 2020. These progress not only enhance the wellbeing of the patients, but also widen the potential uses of stem cells, thus making in-vivo delivery the most dominant method of obtaining stem cells in the market.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America is leading the stem cell therapy market with over 51.86% market share. There are currently more than 3,000 stem cell clinical trials active in the United States, which is more than anywhere else in the world, and they include a variety of cancer, neurological, and cardiovascular conditions. The FDA, which stands for the U.S. Food and Drug Administration, has sanctioned over 20 stem cell therapies such as those for the treatment of hematologic cancers including leukemia and lymphoma. Clinically, the total number of stem cell transplants carried out in the United States has exceeded over 1.5 million, which indicates the country’s significant proficiency in this area. Canada too shows considerable participation in this area with organizations such as the Stem Cell Network providing more than CAD 120 million since its establishment, funding in excess of 200 research initiatives and promoting cross-institutional partnerships amongst more than 40 Canadian institutions.

The academic and medical community in this stem cell therapy market has well developed research facilities and has several niche stem cell research centers. This includes, for example, the stem cell Institute at Harvard University, Stanford Institute for Stem Cell Biology and regenerative medicine in the USA, and Ontario Institute for Regenerative Medicine in Canada. As of Oct 2023, NIH maintains an annual budget of over $3 billion specifically for stem cell research, which covers thousands of studies throughout the country. After the year 2020, for example, more than 4,000 applications for stem cell related patents have been submitted by US nationals. This points out the higher tendency of inventions and their commercialization possibilities in the region/country. Biotechnology appear to be flourishing in the US and Canada where there are over 900 stem cell biotechnology firms that have stem cell research and development programs. More than 50 universities in North America offer related degree programs with more than 60 educational programs. Courses include stem cell biology and regenerative medicine. Such a massive number of graduates ensures a more stable entering to the industry.

Some North American researchers in the stem cell therapy market have furthered world knowledge by publishing up to 15,000 stem cell research articles yearly and managing numerous peer-reviewed citations. More than 1,000 Investigational New Drug applications have been approved by the FDA for stem cell therapies which in turn has allowed the commencement of clinical trials of new therapies. Well over, 300 centers for stem cell therapy operating at all level of the region cater for regulated therapies. Stem cell projects in Canada are growing as well, with government support for more than 30 facilities across the country. Furthermore, more than 1,200 clinical trials aimed at treating certain types of cancer and diseases with stem cells are being conducted in this area as well. 

Top Players in Stem Cell Therapy Market

• Thermo Fisher Scientific, Inc
• AlloSource
• STEMCELL Technologies, Inc.
• Merck KGaA
• Sartorius AG (CellGenix GmbH)
• PromoCell GmbH
• Takara Holdings, Inc.
• Lonza
• ATCC
• AcceGen
• Cell Applications, Inc.
• Bio-Techne
• Cellular Engineering Technologies
• Mesoblast Ltd
• Other Prominent Players

Market Segmentation Overview:

By Cell Source

• Adipose tissue-derived MSCs (mesenchymal stem cells)
• Bone marrow-derived MSCs
• Placental and umbilical cord-derived MSCs
• Other Cell Sources

By Type

• Autologous stem cell therapy
• Allogeneic Stem Cell Therapy

By Delivery Method

• In Vivo
• Ex Vivo

By Therapeutic Use

• Oncology
• Musculoskeletal disorders
• Wounds and injuries
• Cardiovascular system diseases
• Surgery
• Inflammatory and autoimmune diseases
• Nervous system disorders
• Drug Discovery
• Others

By End User

• Hospitals
• Ambulatory Surgical Centres
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America